updat model pt
updat model pt
earn guidanc compani remain confid
doubl digit earn growth despit multipl
growth driver bright spot includ venclexta well
new emerg product orilissa risa
upa upsid surpris could come
venclexta myeloma oncolog pipelin
pair better target platform stemcentrx
target given level skeptic believ
outperform simpli hit bottom line
despit ou humira eros increas
comment addit signific ou
countri expect biosimilar entri
orilissa formulari access increas
model revis pt
increas outlook new product launch
decreas termin growth rate
account slower growth
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
growth driven volum
impact retail inventori
destock larg specialti pharci
us benefit shipment time
across approv
modest stock benefit
launch new formul
expect ou eros
moder
europ ou
eros
biosimilar entri
ou countri
market share gain across line
therapi cll
continu uptak
report roch
pt start
increas uptak
mavyret market lead
posit us strong
leadership posit
number ex-u market
mavryet
intern result fewer
us market share access
cover live mavyret sale
total primarili daa
failur patient japan
benefit time
note fy
us intern
note fy
note fy
global hcv
hcv sale
note fy
line
y/i
y/i midpoint
y/i
fy rate
impact
y/i
approv juli
launch on-going build awar
broad coverag start jan averag
approv juli endometriosi
present uterin fibroid data
asrm regulatori submiss
uterin fibroid
shine mcl perspect fl
selen r/r fl mzl
data asrm regulatori
submiss uterin fibroid
present illumin
capitiv data work
cll studi young fit watch
wait patient on-going data young
fit patient expect
addit cll data next
present uterin fibroid data aagl
submit snda
submit snda mid-
gazyva allianc imb mono combo
strong data
 vs br data expand cll
efficaci vs fcr
cll
addit cll data next year
cll data
cll studi cll
launch broad r/r cll
present upcom confer
submit snda aml
receiv induct therapi jul data
aml
aml receiv induct therapi
aml market condit
approv confirmatori result
possibl data mm target
subset fairli substanti
patient good fit inhibitor
bellini mm studi
start pivot mm mcl
bellini mm studi initi
studi mm
bellini mm studi
submit nda commerci
expect
pdufa note
start cd ad
present uc data ueg
submit bla bla
start cd
present addit data ra acr
begin gca on-going
begin giant cell
on-going studi cd on-going uc
expect initi
jak/btk combo began ra
begin lupu
antagonist transit uc
anti-tnf steroid
begin
file impair charg rova-t
taho stop dec due
shorter os rova-t arm compar
gbm data
gbm data
vela data non-squam nsclc present data
take cf program up-front
royalti glpg work chemistri
meru mainten sclc
like data
later
triniti data present
file acceler approv sclc
possibl data combo i/o data
meru taho data
expect
colorect cancer sc-
ovarian cancer data
vela data non-squam nsclc
proceed second tripl
combo glpg review futur cf
collabor
deriv pt use dcf discount rate termin
growth rate discount rate standard rate appli across derisk biopharma compani
reflect believ appropri return sharehold termin growth rate reflect
durabl natur compani biolog franchis
clearli humira domin product framework biosimilar adopt chang humira
method use patent fall multipl biosimilar launch simultan creat pent-up
precipit impact sale share could suffer
articl articl
time dissemin januari
analyst josh schimmer shenston huang ami liu maneka mirchandaney primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
